ABUS
Arbutus Biopharma Corporation
NASDAQ · Healthcare · Biotechnology · US
$5.15
+0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 181.7M | 14.1M | 6.2M | 18.1M | 39.0M |
| Cost of Revenue | 33.0K | 363.0K | — | — | — |
| Gross Profit | 181.7M | 13.7M | 6.2M | 18.1M | 39.0M |
| Operating Expenses | |||||
| R&D Expense | 17.8M | 25.2M | 54.0M | 73.7M | 84.4M |
| SG&A Expense | 16.5M | 15.9M | 22.1M | 22.5M | 17.8M |
| General & Admin Expense | 16.5M | 15.9M | 22.1M | 22.5M | 17.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 191.0K | (363.0K) | 6.3M | 69.0K | 2.2M |
| Total Operating Expenses | 34.5M | 40.8M | 82.5M | 96.2M | 104.5M |
| Cost and Expenses | 34.5M | 41.1M | 82.5M | 96.2M | 104.5M |
| Operating Income (EBIT) | 147.2M | (27.1M) | (76.3M) | (78.1M) | (65.5M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 4.1M | 6.6M | 5.7M | 2.2M |
| Interest Expense | 76.0K | 97.0K | 137.0K | 459.0K | 1.7M |
| Net Interest Income | 3.4M | 4.0M | 6.4M | 5.2M | 466.0K |
| Other Non-Op Income/Expense | 5.8M | (6.5M) | 6.4M | 5.3M | 444.0K |
| Non-Operating Income (excl Interest) | (5.9M) | 6.4M | (6.5M) | (5.7M) | (2.2M) |
| EBT (Pre-Tax Income) | 153.1M | (33.5M) | (69.9M) | (72.8M) | (65.0M) |
| Income Tax Expense | — | — | — | — | 4.4M |
| Bottom Line | |||||
| Net Income | 153.1M | (33.5M) | (69.9M) | (72.8M) | (69.5M) |
| Earnings from Cont. Ops | 153.1M | (33.5M) | (69.9M) | (72.8M) | (69.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 153.1M | (33.5M) | (69.9M) | (72.8M) | (69.5M) |
| Per Share | |||||
| Basic EPS | $0.79 | ($0.17) | ($0.38) | ($0.44) | ($0.46) |
| Diluted EPS | $0.78 | ($0.17) | ($0.38) | ($0.44) | ($0.46) |
| Revenue Per Share | $0.92 | $0.07 | $0.03 | $0.11 | $0.26 |
| Shares | |||||
| Basic Shares Outstanding | 197.5M | 191.6M | 185.6M | 166.0M | 150.9M |
| Diluted Shares Outstanding | 197.5M | 191.6M | 185.6M | 166.0M | 150.9M |
| Profitability Metrics | |||||
| EBITDA | 153.2M | (33.0M) | (68.4M) | (71.0M) | (61.9M) |
| D&A | 44.0K | 363.0K | 1.4M | 1.4M | 1.4M |
| EBIT | 153.1M | (33.4M) | (69.8M) | (72.4M) | (63.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026